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SignalingAutosomal dominant polycystic kidney disease (ADPKD) is a prevalent, inherited condition for which there is
currently no effective speciﬁc clinical therapy. The disease is characterized by the progressive development of
ﬂuid-ﬁlled cysts derived from renal tubular epithelial cells which gradually compress the parenchyma and
compromise renal function. Current interests in the ﬁeld focus on understanding and exploiting signaling
mechanisms underlying disease pathogenesis as well as delineating the role of the primary cilium in
cystogenesis. This review highlights the pathogenetic pathways underlying renal cyst formation as well as
novel therapeutic targets for the treatment of PKD. This article is part of a Special Issue entitled: Polycystic
Kidney Disease.stic Kidney Disease.
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On gross pathological examination, the polycystic kidney is
impressive. The profound morphological disorganization of a tissue
that is normally an exquisite exemplar of elegant design speaks to
the magnitude of the cellular de-differentiation and dysregulation
that can occur as a consequence of relatively small genetic
alterations. Autosomal dominant polycystic kidney disease is fairly
common, affecting between 1 in 500 and 1 in 1000 people. The
disease is characterized by the slow development, over decades, of
large ﬂuid ﬁlled cysts in the kidneys. These cysts dramatically enlarge
the kidneys and, more importantly, severely compromise the
functional integrity of the remaining normal parenchyma. Clinically
signiﬁcant impairments of renal function will usually occur by late
middle age. Roughly 50% of ADPKD patients will progress to end
stage renal disease, requiring transplant or dialysis [1–3]. There is
substantial variability in disease presentation, even within families.
Although this heterogeneity can be explained by the variable nature
of disease causing somatic mutations, modiﬁer genes may also be
inherited independently of the PKD mutation. These modiﬁers may
include the angiotensin-1-converting enzyme (ACE) gene, the CFTR
gene or the Tuberous Sclerosis Complex-2 gene, all of which may
affect disease severity [4–9]. Although poor prognostic factors such
as hypertension, early onset, male gender, increased kidney size and
rate of growth, and microalbuminuria have been identiﬁed, the
reasons for some of these apparent correlations are less well
understood [10–17].Most patients present with ﬂank pain, hypertension, hematuria,
renal insufﬁciency, and/or proteinuria. The ﬂank pain may be
secondary to calculi, renal hemorrhage, or be due to a urinary tract
infection [2]. Renal function begins to decline in the fourth decade of
life with the glomerular ﬁltration rate (GFR) decreasing by 4.4 to
5.9 mL/min per year [1]. The decrease in GFR is inversely proportional
to kidney size and cyst volume as assessed by the Consortium for
Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) [18–
20]. Because ultrasound measurements cannot discern changes in
kidney size over short time intervals, magnetic resonance imaging
(MRI) with or without gadolinium has become the gold standard for
assessing changes in kidney volume and thereby prognosis [21,22].
As there is no speciﬁc or targeted clinically approved therapy,
current practice focuses on strict blood pressure control with ACE
inhibition and the use of statins to reduce the associated cardiac
mortality that coincides with chronic kidney disease [23]. Some
patients experience abdominal and back pain from the enlarged
kidneys and in these cases relief may be obtained via partial or
total nephrectomy, or sclerosis of the cysts [24]. These procedures
may also be required to accommodate an allograft. For those
patients who progress to end stage renal disease, the options are
limited to dialysis or renal transplantation. Hemodialysis is often
preferred for technical ease in the setting of enlarged kidneys,
and the outcomes of patients on dialysis are comparable to or
better than those of non-ADPKD patients [25]. Mortality in
patients with ADPKD is most often attributable to cardiac disease,
infection, intracranial aneurysm, and hypertensive intracerebral
hemorrhages [26].
Amongst ADPKD patients, 85–90% of cases result from mutations
in PKD1, while another 10–15% of cases are accounted for by
mutations in PKD2 [27]. There are also a small number of families
with classic presentations of PKD whose members appear to have
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that a third locus may be involved [28–30]. Patients with mutations in
PKD1 experience a more severe phenotype, with one study reporting
a median age of death or onset of end-stage renal disease of 54.3 years
versus 74.0 years for patients with PKD2 mutations [31]. This
discrepancy is hypothesized to result from increased cyst number,
not size [32]. At present, over 300 truncating mutations of PKD1 and
91 mutations of PKD2 have been identiﬁed in patients with ADPKD.
There are approximately another 100 disease-causing mutations
which are missense [1]. Given this large database, molecular
diagnostics are now becoming an option for situations when imaging
studies are inconclusive, for when patients wish to know their genetic
predisposition, or when the question of organ donation arises [33].
Interestingly, greater than 10% of patients come from families in
which neither parent is affected [1].
PKD1 (polycystic kidney disease 1, ch16p13.3, 46 exons) encodes
polycystin-1 (PC-1), a 462 kD, 4303 amino acid integral membrane
protein with 11 transmembrane domains, a long extracellular N-
terminus with multiple binding domains and a short cytoplasmic C-
terminus that interacts with multiple proteins, including the protein
product of PKD2 (polycystic kidney disease 2, ch4q21, 15 exons),
polycystin-2 [3]. Polycystin-2 (PC-2) is a signiﬁcantly smaller 110 kD
protein with six transmembrane domains.
Both of the polycystin proteins exhibit complex subcellular
localizations. Polycystin-1 is found in the basolateral plasma mem-
brane domain of polarized epithelial cells, where it participates both
in intercellular adherence junctions and in focal adhesion complexes
with the underlying basement membrane [34]. In addition, a cleavage
product of PC-1 that includes the C-terminal tail can translocate to the
nucleus to regulate gene transcription [35,36]. Most of the polycystin-
2 protein is concentrated in intracellular compartments, where it
appears to play a role in regulating the release of calcium from
intracellular stores. Its role as a cation channel is consistent with the
fact that it is a member of the TRP family of ion channels [37]. PC-2
may also play a role in cellular proliferation and differentiation by
controlling cell cycle regulation [38]. Both PC-1 and PC-2 are localized
to the primary cilium that graces the apical surfaces of most polarized
epithelial cell types. This non-motile, chemo- and mechano-sensory
structure seems to be critically intertwined in the pathophysiology of
renal cystic disease. Mutations in many genes that encode proteins
involved in ciliary function lead to some manner of cystic disease
[39,40].
While the exact physiological and pathological roles of these two
proteins are still debated, it is clear that renal cystogenesis occurs
when both copies of one or the other polycystin gene are either
mutated or knocked out [41,42]. In mice, homozygous mutations of
PKD1 and PKD2 result in embryonic lethality at E12.6–16.5 [42].
Heterozygous mice appear essentially phenotypically normal, occa-
sionally developing a few hepatic and renal cysts later in life [43]. In
addition, decreasing PKD1 expression is sufﬁcient to cause cystic
disease in mice [44] while overexpression of polycystin-1 in
transgenic mice also results in renal cyst formation [45]. A study
by Piontek et al. revealed that inactivation of PKD1 prior to
postnatal day 13 in conditional knockout mice results in an
extremely rapid disease course of cyst development, while inacti-
vation after this developmental time point results in much milder
disease progression [46,47]. These ﬁndings suggest that the
polycystin proteins may function as important “brakes” on cell
growth and division during renal development and that rapid
proliferation of renal epithelial cells, such as occurs during renal
development, may create an environment that facilitates the cellular
consequences of polycystin mutation to become manifest. There is
also evidence for a trans-heterozygous model of ADPKD, consistent
with a two-hit hypothesis for disease initiation [48]. A third-hit
model has also been proposed, in which renal injury stimulates
the rapid cellular proliferation that, as noted above, may be aprerequisite for the cystic changes to occur after somatic
mutagenesis or in association with reduced polycystin expression.
This model may explain, at least in part, why disease initiation
occurs so long after the initial genetic insult [49].
2. Introduction to the primary cilium: a rediscovered organelle
Eukaryotic cilia are microtubule-based structures that can be
either motile or non-motile. Motile cilia are found in groups, lining
large epithelial surfaces such as those of the trachea or cerebral
ventricles, where they serve to clear mucus [50,51] or circulate
cerebral spinal ﬂuid [50,52,53], respectively. Non-motile or primary
cilia, in contrast, are solitary, specialized ‘antennae’-like protrusions
that extend markedly above the cell surface of nearly every cell in the
vertebrate organism [54].
First described over 110 years ago, the exact function of these
appendages in, or rather on, the cell remains elusive even today [55].
Because cilia project out and above the cell surface, they are
currently thought to function in sensing and responding to the
extracellular environment [56]. Structurally distinct from motile cilia,
primary cilia have reappeared in the spotlight because recent data
suggest these structures play important roles in photo-, chemo-, and
mechanosensation [57]. Thus, the primary cilium may be structurally
adapted to translate a variety of extracellular signals into intracel-
lular signals. Furthermore, ciliary defects may be the common
mechanism responsible for a heterogeneous group of disorders
including renal cystic disease, retinal degeneration, anosmia (as in
Bardet–Biedl syndrome), situs inversus, and neural tube defects
[54,58,59].
Dividing cells are thought to be incapable of cilium formation
because the basal body (one of the cell's centrioles) is required for the
assembly of the mitotic apparatus [60,61]. Therefore, ciliogenesis is
expected to occur when cells have enteredmitotic quiescence [62,63].
Conversely, the presence of the cilium may in itself act to prevent cell
division, since the basal body centriole is not available for the
formation of the mitotic spindle. Thus, regulated ciliary disassembly
may be an important factor in controlling proliferation, and
perturbations in cilia formation might be expected to lead to hyper-
proliferative states.
3. Primarily cilium structure and function
As early as 1962, Sorokin et al. attempted to explain the differences
in development between primary cilia and motile cilia [64]. Motile
cilia have a 9+2 arrangement, with a pair of singlet microtubules in
the center, connected by radial spokes to nine doublets in the
periphery. In contrast, primary cilia have a 9+0 microtubule
arrangement with nine doublets along the periphery [65]. Although
contiguous with the apical membrane, the ciliary membrane's lipid
and protein composition is distinct [66]. Moreover, at the transition
point from the plasma membrane to the ciliary membrane, the triplet
microtubules of the basal body centriole transform into double
microtubules within the ciliary axoneme [67].
The ﬁrst steps in ciliation involve the modiﬁcation and movement
of the designated centriole to a position below the apical membrane
[68]. In the G1 phase of cell division, each cell contains one centriole
(mother centriole) that acts as a template for the assembly of the
other centriole (daughter centriole). Although structurally indistin-
guishable, it is always the mother centriole that serves as both the
microtubule organizing center and the core structure of the basal
body [69].
At the base of the primary cilium lies the basal body, which is the
mother centriole, modiﬁed to include transition ﬁbers, basal feet, and
rootlets. The transition ﬁbers of the basal body connect the
microtubules to the plasma membrane [70]. Appearing like ‘pin-
wheels’ in cross-section, these structures are may participate in
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have suggested that transition ﬁbers could serve as docking platforms
for molecules involved in cilium construction as well as for ciliary
cargo [71]. Basal feet are lateral projections below the transition ﬁbers
andmost likely connect the microtubules in the cytoplasm to the base
of the cilium. Finally, ciliary rootlets extend from the basal body deep
into the cell, and may even contact the Golgi apparatus [72]. Most
likely these rootlets act like tentacles that penetrate the cell to secure
a foundation for the cilium. However, it is also conceivable, given the
connections with the Golgi apparatus, that these rootlets allow for
selective transport of cargo directly to the ciliary membrane. In effect,
the structures of the basal body may be important not only for
maintaining ciliary structure, but also for selecting and targeting
proteins to the ciliary membrane.
All of the proteins required for ciliary assembly, sensation, and
signaling must be transported from within the cell to the very tip of
the cilium, as cilia lack ribosomes. A microtubule based “conveyer
belt” shuttles proteins along the ciliary axoneme in a process known
as intraﬂagellar transport (IFT) [73]. IFT was initially discovered in the
green algae Chlamydomonas and has since been found to occur in
other ciliated eukaryotes [74–76]. In this process, proteins gather into
IFT particles at the base of the cilium and these particles are then
transported up the cilia via kinesin motors and downwards via a
dyneinmotor protein. The importance of this process in the context of
the present discussion of renal cystic disease is highlighted by the
consequences that result from the kidney-speciﬁc inactivation of the
gene encoding the Kif3a subunit of kinesin-II in mice. This genetic
manipulation results in the absence of cilia in affected nephron
epithelial cells. In addition, these mice develop severe renal cystic
disease that resembles the pathology associated with PKD [77]. Using
IFT, the cell can deliver important structural and signaling molecules
into the cilium and, as a consequence, the cilium can transmit
information regarding the external milieu back to the cell [78,79].4. Ciliopathies and renal cystic disease
In recent years, considerable interest has developed in the primary
cilium as a locale for proteins involved in renal cystogenesis. One of
the ﬁrst discoveries that associated the primary cilium to cystic
disease involved the demonstration that the Tg737 gene, whose
function was disrupted in the Oak Ridge Polycystic Kidney mouse
(Tg737orpk) [80], was in fact an ortholog of the Chlamydomonas
Intraﬂagellar Transport Protein 88 (IFT88) [81]. Although the IFT88
mutant mice were already known to have developmental defects
including cystic kidneys, the suggestion that a gene involved in ciliary
assembly could cause such defects was new and important [82].
GFP-tagged versions of the mammalian polycystin-1 and poly-
cystin-2 orthologs were localized to the ciliated tips of Caenorhabditis
elegans male sensory neurons, and subsequently both polycystins
were co-localized with the primary cilium in human and mouse
kidney cell lines [83–85]. Interestingly, in addition to the polycystins,
the protein responsible for ARPKD, ﬁbrocystin, and the proteins
responsible for the recessively inherited nephronophtheses, also co-
localize with the cilium or the basal body [86–88]. Ciliary polycystins
may play a part in coordinating a cellular response to changes in
extracellular ﬂuid ﬂow. Praetorius and Spring have demonstrated that
ciliary bending triggered by ﬂuid ﬂow results in an increase in
intracellular calcium suggesting that the primary cilium may function
as a mechanosensor [79,89,90]. It has been suggested that polycystin-
1 and polycystin-2 may mediate this process, at least in part, by
forming a mechanosensory complex that responds to shear stress by
increasing cytoplasmic calcium [91–94]. Alternatively, or in addition,
the polycystins may be responsible for governing cellular processes
via the JAK/STAT [36,95], p53 [96], mTOR [97], NFAT/AP-1 [98] or Wnt
signaling pathways [35,36,99]. If the polycystins are mutated, thenpresumably one or more of these cellular signaling functions are
compromised, and cystogenesis ensues.
Proteins involved in key developmental signaling pathways,
including those of the Wnt, hedgehog, and planar cell polarity
pathways, are physically located in the cilium, lending further support
to the hypothesis that this structure is somehow regulating
proliferation by sensing the extracellular environment [100–104]. In
addition to ADPKD, ARPKD and the nephronophtheses, a large
number of syndromes, including Bardet–Biedl syndrome (in which
patients have both renal cystic disease and anosmia), Kartagener's
syndrome, Meckel–Gruber Syndrome, Joubert syndrome and Oro-
facial-digital type 1, syndrome have been recognized to be associated
with abnormal ciliogenesis or with disease-speciﬁc proteins that co-
localize with cilia [105]. As more and more proteins are linked to the
primary cilium, the list of these ciliopathies will doubtlessly continue
to grow.
5. Mechanism of cyst growth — ﬂuid secretion
Examined at a more macroscopic level, cysts originate as
dilatations in the walls of intact tubules, initially ﬁlling from ﬂuid
ﬁltered in the glomerulus [106]. However, as the cysts enlarge, they
lose their connections to the parent nephron [106]. It is unclear what
event(s) initiate cyst formation in ADPKD or what factors determine
cyst localization along the nephron, although there is clearly an
associationwith genetic predispositions that result in either abnormal
cellular differentiation or maturation [106–108]. These abnormal
cellular responses are hypothesized to arise, at least in part, from
abnormal cilium formation [107,109], abnormal protein targeting
[85,110], cyclic AMP activation [106,111,112], and unregulated cell
proliferation and growth [113–116].
The pathological processes that facilitate cyst enlargement,
however, are hypothesized to result from two speciﬁc cellular
abnormalities: 1) increased ﬂuid secretion into the cyst lumen and
2) inappropriately increased cell division of the cyst lining epithelium.
The increased secretion might be expected to increase the hydrostatic
pressure inside the cyst and encourage expansion, while the increase
in cell proliferation would simultaneously induce de novo cyst
formation. Grantham et al. have demonstrated that the rate of ﬂuid
secretion into the cyst lumen is directly proportional to the amount of
the CFTR chloride channel present in the apical membrane. These data
are consistent with the role for ﬂuid secretion in driving cyst growth
[117]. The epithelial cells that line the nephron normally function to
drive the net absorption of ﬂuid and electrolytes. In vitro estimates of
cyst ﬂuid production by PKD cells range from 26 to 475 ml per year
[118]. Thus, PKD can be thought of, at least in part, as a disease in
which the normally absorptive cells of the renal tubule adopt a largely
secretory phenotype.
In the prevailing physiological model for ﬂuid secretion by renal
cyst epithelia cells, the Na,K-ATPase in the basolateral membrane
mediates sodium extrusion in exchange for potassium uptake. Sodium
re-enters the cell via a basolateral isoform of the sodium–potassium
chloride cotransporter (NKCC1), which drives secondary active
basolateral chloride entry. This chloride exits apically via the CFTR
channel, driven by the electrochemical gradient for chloride across the
apical membrane. The chloride ﬂux drives paracellular sodium and
water movement, thus promoting ﬂuid accumulation within the cyst
lumen [119]. A basolateral potassium channel is also required in order
to allow egress of potassium that enters via the Na,K-ATPase and
NKCC1 [120]. It is interesting to note that within the small cohort of
patients that suffer from both cystic ﬁbrosis and PKD, the PKD
progression is slower than average, presumably because the mutated
CFTR channel is unable participate in ﬂuid secretion into the cysts
[121]. The evidence for CFTR acting as a signiﬁcant contributor to cyst
growth has inspired pre-clinical trials of CFTR-inhibitors in animal
models of PKD [122,123].
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levels of cAMP [124]. A large body of research indicates that cytosolic
cAMP levels are elevated in renal cyst epithelial cells, perhaps as a
consequence of the presence of autocrine or paracrine factors secreted
into cyst lumens [111]. In addition, cAMP appears to constitute a
powerful mitogenic stimulus for cyst epithelial cells [125,126]. Thus,
both of the major phenotypic perturbations exhibited by ADPKD
epithelial cells—excessive proliferation and ﬂuid secretion—may be
under the control of inappropriately elevated levels of cAMP.
6. Potential therapies for polycystic kidney disease
Recent advances in the understanding of pathways governing
renal cystogenesis have led to a number of intriguing possibilities for
therapeutic intervention. Some pathways target ﬂuid secretion, while
others target cellular growth and proliferation. cAMP was one of the
ﬁrst molecules implicated in the hyper-secretory phenotype of cyst
formation that has been targeted by speciﬁc therapeutic interven-
tions. Increased cAMP levels are a common feature of most models of
PKD [127–129]. cAMP is also involved in the stimulation of the MAPK/
ERK signaling pathway via Src and Ras [130]. Although the precise
mechanism underlying the increase in cAMP is not known, it has been
noted that vasopressin levels are increased in human ADPKD [131].
Upregulation of the vasopressin V2 (V2) receptor is also found in the
cpk, pcy, and PKD2(WS25/−) mouse models, and PCK rat model of
cystic disease [127,128,132]. The V2 receptor stimulates cAMP
accumulation. Blockers of the V2 receptor have produced impressive
therapeutic effects in animal models of cystic disease [127]. In
addition, activating the somatostatin receptor reduces cellular cAMP
levels, and somatostatin analogues have also produced promising
results in human trials [133]. Ongoing clinical trials are currently
evaluating the efﬁcacy of the V2 receptor antagonist, tolvaptan, and
long-acting somatostatins [134,135]. Other potential therapies that
are directed at addressing ﬂuid secretion include CFTR inhibitors and
KCa3.1 inhibitors, which inhibit the basolateral potassium channel
necessary for cAMP-dependent chloride secretion [120,136].
Although the pathways governing proliferation are complex and
somewhat intertwined, a number of potential therapies have emerged
that speciﬁcally target upregulated pathways. Given the parallels
between the hyper-proliferative phenotype of PKD and the unregu-
lated cell division in neoplasia, several chemotherapeutic agents have
been explored in efforts to decrease cyst growth. These therapies
include paclitaxel, epidermal growth factor receptor (EGFR) tyrosine
kinase inhibition, TNF-α converting enzyme inhibition, and c-SRC
inhibition [137,138]. While some of these agents have produced
impressive results in animal models, it is important to note that these
anti-mitotic agentsmust be tolerated over a patient's entire lifetime in
order to be useful as a therapy for ADPKD, as it is likely that cyst
growth will resume as soon as inhibition of proliferation is removed.
Several interesting potential target molecules for drug therapies
have been found to be upregulated speciﬁcally in PKD. Efforts to
exploit some of these potential targets have explored agents directed
at CyclinD [139], B-raf [140], and mitogen-activated protein kinase/
extracellular signal-regulated kinase (MAPK/ERK) kinase [141].
Intriguingly, it has also been shown that mammalian Target of
Rapamycin (mTOR) activity is elevated in models of PKD [142]. mTOR
is a serine/threonine kinase that regulates cell growth and prolifer-
ation, as well as transcription and protein synthesis. Shillingford et al.
have reported that mTOR is regulated by polycystin-1 [97]. Rapamy-
cin, also known as sirolimus, binds to FK506-binding protein (FKBP)
and this complex then binds to and inhibits mTOR's kinase activity
[143,144]. Indeed, treatment with rapamycin has been shown to
improve renal cystic indices in the orpk and Tg737 rescue models for
cystic kidney disease as well as the Han:SPRD rat model of ADPKD
[97,142,145]. Unfortunately, recent Phase II trials of the utility of
mTOR inhibitors such as everolimus and sirolimus for the treatment ofPKD did not indicate substantial therapeutic efﬁcacy [146–148].
Efforts are also being made to inhibit mTOR signaling less directly and
perhaps with less toxicity through agents that produce TNF-α
inhibition or through AMPK stimulation via metformin [149].
Investigators have used MEK inhibitors to diminish proliferation
induced by MAPK/ERK signaling, which results from ligands present
in cyst ﬂuid that bind to and activate tyrosine kinase receptors [141].
Further down this pathway, Bukanov et al. have posited roscovitine, a
cyclin-dependent kinase (CDK) inhibitor, as another potential therapy
for human patients, given its relatively low adverse side effect proﬁle
[139,150]. Inhibition of the synthesis of glucosylceramide produces
dramatic therapeutic effects in mouse models of ADPKD, [151]
although the cellular mechanisms responsible for this effect remain
to be thoroughly elucidated. Finally, histone deacetylases have
emerged as promising targets that may be exploited for ADPKD
therapeutic development [152,153].
7. Conclusion
Renal cystogenesis is characterized by the pathologic accumula-
tion of ﬂuid in epithelium lined cavities leading to the destruction of
adjacent normal parenchyma. Inherited cystic diseases, including the
most prevalent form, ADPKD, are hypothesized to result from
abnormalities in proteins required for the proper formation and
function of primary, nonmotile cilia in epithelial renal tubules.
Although disruptions in cilia formation or mutations in proteins that
co-localize with the cilium are associated with renal cyst develop-
ment, the exact relationship between cystogenesis and ciliogenesis is
unclear. Our incomplete understanding of cyst pathogenesis has
hampered the development of speciﬁc clinical therapies. At present,
there are no FDA-approved therapies for the treatment of PKD, and
patients who progress to end-stage renal disease require renal
replacement therapy. Recent research has suggested a number of
promising target molecules and pathways, and extensive efforts are
underway to explore and exploit these new avenues.
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